🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, escalating drug resistance and the very limited treatment choices presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the therapy of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Results and Worldwide Availability

According to findings detailed in a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an comparable level with the typical regimen, which involves a dual-drug approach. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of developing nations.

Doctors directly involved have voiced optimism. Access to a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is considered essential to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.